节点文献
甘草查尔酮A通过miR-486-5p/SRPK1分子轴影响骨肉瘤细胞增殖和凋亡的研究
Research of licochalcone A affects osteosarcoma cell proliferation and apoptosis via the miR-486-5p/SRPK1 axis
【摘要】 目的 研究甘草查尔酮A(LCA)通过调控微小RNA(miR)-486-5p/丝氨酸精氨酸蛋白激酶1(SRPK1)分子轴对骨肉瘤细胞增殖和凋亡的影响。方法 取HOS细胞分为HOS组(正常培养)、LCA组(20μmol·L-1 LCA)、LCA+miR-486-5p mimics组(转染miR-486-5p mimics+20μmol·L-1 LCA)、LCA+oe-SRPK1组(转染oe-SRPK1+20μmol·L-1 LCA)和LCA+oe-SRPK1+miR-486-5p mimics组(共转染oe-SRPK1和miR-486-5p mimics+20μmol·L-1 LCA)。用实时荧光定量聚合酶链反应法检测miR-486-5p和SRPK1相对表达水平,用蛋白质印迹法检测SRPK1蛋白相对表达水平及磷脂酰肌醇-3-激酶(PI3K)/蛋白激酶B(AKT)信号通路相关蛋白PI3K和AKT的磷酸化水平,用5-乙炔基-2’脱氧尿嘧啶核苷法检测细胞增殖情况,用原位末端转移酶标记法检测细胞凋亡情况,用试剂盒检测乳酸和腺苷三磷酸(ATP)水平。结果 0、5、10和20μmol·L-1组的miR-486-5p相对表达水平分别为1.00±0.09、1.15±0.12、1.35±0.22和1.44±0.26;HOS组、LCA组、LCA+miR-486-5p mimics组、LCA+oe-SRPK1组和LCA+oe-SRPK1+miR-486-5p mimics组的细胞增殖率分别为(81.26±7.26)%、(36.51±4.96)%、(21.36±5.31)%、(49.75±5.42)%和(30.18±5.46)%,细胞凋亡率分别为(6.53±1.57)%、(27.56±8.29)%、(46.32±12.37)%、(18.44±6.51)%和(39.10±9.83)%,乳酸水平分别为(0.45±0.05)、(0.23±0.03)、(0.18±0.02)、(0.41±0.05)和(0.31±0.03)mmol·g-1,ATP水平分别为(13.46±1.55)、(6.22±1.13)、(5.07±0.67)、(9.58±1.26)和(7.37±1.14)μmol·g-1,p-PI3K/PI3K水平分别为1.00±0.13、0.61±0.06、0.49±0.05、0.77±0.08和0.65±0.07,p-AKT/AKT水平分别为1.00±0.14、0.59±0.06、0.47±0.05、0.79±0.08和0.61±0.07,HOS组与LCA组相比、LCA+miR-486-5p mimics组、LCA+oe-SRPK1组与LCA组相比、LCA+oe-SRPK1+miR-486-5p mimics组与LCA+oe-SRPK1组相比,以上指标在统计学上差异均有统计学意义(P<0.05,P<0.01,P<0.001)。结论 LCA能够抑制骨肉瘤细胞增殖、促进凋亡,并调节细胞能量代谢,可能与通过miR-486-5p/SRPK1轴调控PI3K/AKT信号通路有关。
【Abstract】 Objective To investigate the effect of licochalcone A(LCA) on osteosarcoma cell proliferation and apoptosis by regulating the microRNA(miR)-486-5p/serine arginine protein kinase 1(SRPK1)axis.Methods HOS cells were divided into the following groups:HOS group(general culture),LCA group(20 μmol·L-1 LCA),LCA+miR-486-5p mimics group(transfected with miR-486-5p mimics+20 μmol·L-1 LCA),LCA+oe-SRPK1 group(transfected with oe-SRPK1+20 μmol·L-1LCA) and LCA+oe-SRPK1+miR-486-5p mimics group(co-transfected with oe—SRPK1 and miR-486-5p mimics+20 μmol·L-1 LCA).Real-time fluorescence quantitative polymerase chain reaction was used to detect the relative expression levels of miR-486-5p and SRPK1.Western blot was used to detect the protein relative expression levels of SRPK1 and the phosphorylation levels of phosphatidylinositol 3-kinase(PI3K),protein kinase B(AKT) and related proteins in the PI3K/AKT signaling pathway.5-ethynyl-2 ’-deoxyuridine assay was used to detect cell proliferation.In situ terminal transferase dUTP nick end labeling assay was used to detect cell apoptosis.Kits were used to detect lactic acid and adenosine triphosphate(ATP) levels.Results The relative expression levels of miR-486-5p in the 0,5,10 and 20 μmol·L-1 group were 1.00±0.09,1.15±0.12,1.35±0.22 and 1.44±0.26,respectively.The cell proliferation rates of HOS group,LCA group,LCA+miR-486-5p mimics group,LCA+oe-SRPK1 group and LCA+oe-SRPK1+miR-486-5p mimics group were(81.26±7.26) %,(36.51±4.96) %,(21.36±5.31%),(49.75±5.42) % and(30.18±5.46) %,respectively;the cell apoptosis rates were(6.53±1.57) %,(27.56±8.29) %,(46.32±12.37) %,(18.44±6.51) % and(39.10±9.83) %,respectively;the lactic acid levels were(0.45±0.05),(0.23±0.03),(0.18±0.02),(0.41±0.05) and(0.31±0.03) mmol·g-1,respectively;the ATP levels were(13.46±1.55),(6.22±1.13),(5.07±0.67),(9.58±1.26),and(7.37±1.14) μmol·g-1,respectively;the p-PI3K/PI3K levels were1.00±0.13,0.61±0.06,0.49±0.05,0.77±0.08,and 0.65±0.07,respectively;the p-AKT/AKT levels were 1.00±0.14,0.59±0.06,0.47±0.05,0.79±0.08,and 0.61±0.07,respectively;LCA group was compared with HOS group,LCA+miR-486-5p mimics group and LCA+oe-SRPK1 group were compared with LCA group;LCA+oe-SRPK1+miR-486-5p mimics group was compared with the LCA+oe-SRPK1 group,the above indicators all showed statistically significant differences(all P <0.05,P <0.01,P <0.001).Conclusion LCA can inhibit osteosarcoma cell proliferation,promote apoptosis and regulate cell energy metabolism,which may be related to regulating the PI3K/AKT signaling pathway through the miR-486-5p/SRPK1 axis.
【Key words】 licochalcone A; osteosarcoma; microRNA-486-5p; serine arginine protein kinase 1;
- 【文献出处】 中国临床药理学杂志 ,The Chinese Journal of Clinical Pharmacology , 编辑部邮箱 ,2025年14期
- 【分类号】R285
- 【下载频次】16